CFM Pharma is a Dutch clinical‑stage biotech built around VANADIS® , a platform of proprietary organovanadium compounds and delivery technologies that protect and regenerate tissue in multiple acute‑trauma settings.

Lead Indication (cardiology). The first compound, VANADIS® BMOV, targets myocardial infarction, where its multi‑pathway mechanism simultaneously dampens inflammation, oxidative stress and apoptosis. In pre‑clinical models it reduced infarct size by up to 42 %, and Phase 1A confirmed it is safe and well‑tolerated. The program is now Phase 1B ready, with GMP production under way.

Beyond Cardiology, the VANADIS® chemistry drives a patented pipeline for Severe Burns and Acute Kidney Injury, with worldwide exclusivity locked in until 2042.

Commercial outlook. The VANADIS® platform addresses a $3.7 billion myocardial‑infarction market growing 6.8 % annually, with additional upside in severe burns (≈ $3.35 billion burn‑care market by 2030) and acute kidney injury (≈ $2.9 billion AKI therapeutics market by 2030), offering investors clear value‑inflection opportunities through Phase 1B/2A read‑outs, early‑stage licensing and further platform utilization.